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a b s t r a c t
Administration of antivenoms to treat snakebite envenomings has the potential risk of inducing early
adverse reactions. The mechanisms involved in these reactions are unclear. In this study, polyspeciﬁc
antivenom consisting of whole IgG puriﬁed from equine plasma by caprylic acid precipitation was
administered intravenously to non-envenomed horses (n ¼ 47) and cows (n ¼ 20) at a dose of 0.4 mL/kg.
It has been reported that, in humans, this formulation (administered at a dose of 0.4 mL/kg) induces mild
noticeable early adverse reactions, such as fever, vomiting, diarrhea, urticaria, generalized rash,
tachypnea or tachycardia, in about 15e20% of the patients. Unexpectedly, none of the animals receiving
antivenom in our study showed any evidence of early adverse reaction. Moreover, no late adverse
reactions, i.e. serum sickness, were observed during 40 days after antivenom administration. Unlike
studies performed in envenomed humans, our present results were obtained in a group of non-enve-
nomed individuals. It is concluded that, in addition to the physicochemical characteristics of the
formulation, other unknown factors must determine the occurrence of adverse reactions in snakebite
envenomed humans treated with equine-derived antivenoms.
 2010 The International Association for Biologicals. Published by Elsevier Ltd. All rights reserved.
1. Introduction
Snake antivenoms are immunotherapeutic products used to
treat snakebite envenoming. The active substances of these
formulations are immunoglobulins, or immunoglobulin fragments,
puriﬁed from the plasma of animals immunized with snake
venoms [1,2]. Although therapeutic effectiveness of antivenoms has
been widely demonstrated, the occurrence of early adverse reac-
tions associated with their administration remains a matter of
concern and an aspect that must be improved in envenoming
immunotherapy [3].
Early adverse reactions, such as nausea, headache, dizziness,
fever, vomiting, diarrhea, urticaria, generalized rash, tachypnea,
tachycardia, bronchospasm or hypotension, may occur during the
ﬁrst 2 h after administration of antivenom. Depending of their
underlying pathogenic mechanism, early adverse reactions can be
truly IgE-mediated anaphylactic reactions or, more frequently,
anaphylactoid reactions [1].
Anaphylactic reactions are rarely reported during administra-
tion of antivenoms [4]. These reactions occur in patients previously
exposed to heterologous immunoglobulins and correspond to IgE-
mediated type I hypersensitivity. During the ﬁrst exposure, sensi-
tization occurs and IgE antibodies against antivenom proteins are
produced. Then, during a subsequent exposure, the cross-linking of
these IgE antibodies promotes the degranulation of mast cells, with
the release of vasoactive substances that mediate the anaphylactic
reaction [5].
In contrast to anaphylatic reactions, anaphylactoid reactions are
observed in patients who have not been previously exposed to
heterologous protein [1]. The incidence of anaphylactoid reactions
in human patients receiving horse-derived antivenoms ranges
between 5% and 80%, depending on the physicochemical quality of
the product administered [3].
The mechanisms underlying anaphylactoid reactions are not
completely clear at present. They have been related to activation of
the complement system by two differentmechanisms: 1) the action
of immunoglobulin aggregates formed during the process of plasma
fractionation for antivenom production [6], and 2) the formation of
immune complexes between immunoglobulins that constitute the
antivenom and natural anti-equine heterophilic antibodies present
in the plasma of the patients [7,8]. However, there is not a strict
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correlation between the in vitro anticomplementary activity of
antivenoms and the incidence of anaphylactoid reactions at the
clinical setting [9e13]. Thus, the mechanisms of analphylactoid
reactions remain unclear.
In Costa Rica, the Instituto Clodomiro Picado produces poly-
speciﬁc antivenom for the treatment of envenomings induced by
snakes of the family Viperidae in Central America. It consists of
whole IgG puriﬁed from equine plasma by caprylic acid precipita-
tion of non-IgG plasma proteins [14]. In clinical studies performed
in humans, it has been determined that this formulation induces
severe anaphylactic reactions in less than 0.5% of patients and
anaphylactoid reactions in about 15e20% of patients when the
antivenom is administered by the intravenous route [11,15].
However, there is no information documenting the incidence of
adverse reactions in animals.
The present report describes a study designed to determine the
incidence of early and late adverse reactions induced by equine-
derived whole IgG antivenom when it is intravenously adminis-
tered in non-envenomed horses and cows.
2. Materials and methods
2.1. Antivenom
Polyspeciﬁc antivenom was produced by Instituto Clodomiro
Picado (batch 4240108POLQ). This formulation is constituted by
whole IgG molecules. Immunoglobulins were puriﬁed by caprylic
acid precipitation [14] from the plasma of horses immunized with
venoms of the snakes Bothrops asper, Crotalus simus and Lachesis
stenophrys [16]. The antivenom was formulated at a total protein
concentration of 5.7 g/dL, with 0.85 g/dL NaCl, 0.25 g/dL phenol,
and pH 7.2.
2.2. Determination of protein concentration
Protein concentration in antivenom preparations was deter-
mined by the Biuret reaction [17].
2.3. Electrophoretic analysis
Electrophoregram of the antivenom was obtained by poly-
acrylamide gel electrophoresis (SDS-PAGE) at a concentration of
7.5% acrylamide under non-reducing conditions [18]. Gels were
stained with Coomassie Brilliant Blue R-250.
2.4. FPLC analysis
Antivenom samples were analyzed by gel ﬁltration fast-protein
liquid chromatography (FPLC) in a Superdex 200 10/300 GL column
(Amersham Biosciences, Sweden), using 20 mM TriseHCl, 150 mM
NaCl, pH 7.5 as eluent. The ﬂow rate was 0.5 mL/min [19].
2.5. Hypersensitivity skin test
Hypersensitivity skin test was performed by injecting intra-
dermally 200 mL of antivenom diluted 1:10 with isotonic saline
solution, in the left side of the anal fold. As control, 200 mL of
isotonic saline solution were injected in the right side. Animals
were observed for the next 30 min. The diameters of swelling and
erythema of test and control injection sites were recorded [9]. A
skin test was interpreted as positive when the diameter of the
swelling and erythema induced by the antivenom exceeds that
induced by saline solution by 3 mm.
2.6. Administration of antivenom and clinical observation
Forty seven healthy horses (300e350 kg body weight) and
twenty healthy cows (200e250 kg body weight) were injected
intravenously with equine antivenom at a dose of 0.4 mL/kg, which
corresponds to a dose routinely used in the treatment of snakebite
envenomations in these species (insert of polyvalent antivenom for
veterinary use, Instituto Clodomiro Picado). Antivenom was
administered undiluted into the jugular veinwithin 1 min. Animals
were meticulously observed during the following 3 h by a veteri-
narian for the appearance of noticeable manifestations of early
adverse reactions, i.e. fever, diarrhea, urticaria, generalized rash,
tachypnea or tachycardia [15]. In addition to the assessment of early
adverse reactions, animals were observed on a daily basis during 40
days for the appearance of cutaneous manifestations (rash) char-
acteristic of type III hypersensitivity reactions [20]. All procedures
used in this study were approved by the Institutional Committee
for the Care and Use of Laboratory Animals (CICUA) of Universidad
de Costa Rica (project 82-08) and met the International Guiding
Principles for Biomedical Research Involving Animals [21].
2.7. Determination of anti-equine antibodies in the plasma of
treated cows
Blood samples were collected from the jugular vein immediately
before and 40 days after the administration of antivenom in cows.
Blood was allowed to clot at 20e22 C and serumwas separated by
centrifugation. To assess for the presence of bovine antibodies
against equine IgG, microplates were coated with 100 mL of a 5 mg/
dL dilution of the antivenom. After washing the plates ﬁve times
with 0.12 M NaCl, 0.04 M phosphate buffer, pH 7.2 (PBS), 100 mL of
bovine serum samples, diluted 1:1000 in PBS-2% bovine milk (BM),
were added and the plates were incubated for 1 h at 20e22 C.
Then, microplates were washed ﬁve times with PBS. Afterwards,
100 mL of rabbit anti-bovine IgG conjugated with peroxidase,
diluted 1:8000 with PBS-2% BM, were added to each well. Again,
microplates were incubated for 1 h at 20e22 C. After a ﬁnal
washing step, color development was performed by adding 150 mL
H2O2 and o-phenylenediamine (OPD), and the color reaction was
stopped by the addition of 50 mL 1.0 M HCl. Absorbances were
recorded at 492 nm and results were expressed as mean  SD
(n ¼ 3). Determination of bovine antibodies against equine IgG was
performed in 10 of the 20 cows studied.
2.8. Determination of in vitro sensitization of bovine erythrocytes
by equine natural antibodies present in the antivenom
Before injection of antivenom, venous blood samples were
collected from 10 of the 20 cows studied. A solution of 0.04 M
sodium citrate, 0.02M citric acid, 0.08M dextrose, pH 7.2 (ACD)was
used as anticoagulant. After centrifugation, the erythrocyte pellet
was washed ﬁve times with PBS. Then, a 5% (v/v) erythrocyte
suspension in PBS was prepared. Afterwards, 100 mL of a 1:10
dilution of antivenom, or 100 mL of PBS, were mixed with 100 mL of
erythrocyte suspension from each cow. The mixtures were incu-
bated at 20e22 C for 1 min and, after centrifugation at 500  g for
30 s, macroscopic agglutination was observed and graded,
according with the intensity of the reaction, from “no agglutina-
tion” () to “very strong agglutination” (4þ). Antiglobulin test was
carried out by resuspending and washing the mixtures graded as
“no agglutination” and mixing 100 mL of each one with 100 mL of
rabbit anti-equine IgG. After incubation at 20e22 C for 1 min, the
mixtures were centrifuged and observation of macroscopic agglu-
tinationwas recorded as described. This experiment was controlled
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by repeating the same analysis, but substituting the rabbit anti-
equine IgG with normal rabbit serum [22].
2.9. Determination of in vivo sensitization of bovine erythrocytes by
equine natural antibodies present in the antivenom
Venous blood samples were collected from the cows before and
1 h after injection of antivenom, using ACD as anticoagulant.
Erythrocytes from each sample were washed ﬁve times with PBS
and suspensions at 5% (v:v) in PBS were prepared. Then, 100 mL of
each suspension were incubated with 100 mL of rabbit anti-equine
IgG. After incubation at 20e22 C for 1 min, the mixtures were
centrifuged and observation of macroscopic agglutination was
recorded. This experiment was controlled by performing the same
analysis, but substituting the rabbit anti-equine IgG with normal
rabbit serum [22].
2.10. Statistical analysis
The signiﬁcance of the differences between the mean values of
the titres in samples from cows before and 40 days after antivenom
administration was determined by the paired sample Student’s t-
test. A value of p < 0.05 was considered to be signiﬁcant.
3. Results and discussion
3.1. Antivenom
Early adverse reactions to antivenoms may be of two basic
types, i.e. true anaphylactic reaction, mediated by IgE, or anaphy-
lactoid reactions, mediated by mechanisms independent of IgE [1].
Traditionally, it has been accepted that the appearance of anaphy-
lactoid reactions during the administration of antivenoms is asso-
ciated with the anticomplementary activity of the formulations [6].
On this basis, it has been assumed that F(ab’)2-based formulations,
which have lower anticomplementary activity than whole IgG-
based formulations [23], would induce a lower incidence of
anaphylactoid reactions. However, clinical evidence does not
support this presumption since F(ab’)2 antivenoms induce early
adverse reactions with an incidence that varies depending on the
particular product used [11,12,15,24e28]. This suggests that factors
other than the in vitro anticomplementary activity of antivenoms
must be involved in the genesis of anaphylactoid reactions.
Electrophoregram and FPLC analysis of the antivenom used in
this study shows that: 1) more than 90% of the protein content
corresponds to whole IgG, 2) less than 10% of the immunoglobulins
occur as dimers or high molecular mass aggregates, and 3) this
preparation has very low albumin content (Figs. 1 and 2). These
results indicate that the antivenom used in this study has the
physicochemical properties previously described for this formula-
tion [13].
3.2. Hypersensitivity skin test
Hypersensitivity skin test is used to predict possible IgE-medi-
ated anaphylactic reactions induced by a variety of medicines.
However, since anaphylactoid reactions to antivenoms are not
mediated by IgE, snake antivenom skin test has been of low value in
predicting these reactions [9,29], and it is therefore not routinely
recommended in the clinical administration of antivenoms [30,31].
Thus, intradermal skin test in antivenom administration is only
valid for the prediction of type I hypersensitivity, i.e. anaphylactic
reactions. In our study, hypersensitivity skin test was negative for
all of the animals tested. This result means that anaphylactic
reactions (type I hypersensitivity) were not expected to occur in the
injected animals, a prediction that was fully corroborated by the
experimental outcome (see below). These observations were
expected since the cows used in this study had not been previously
exposed to equine immunoglobulin and it is unlikely that horses
would have IgE against their own IgG immunoglobulins without
showing clinical manifestations.
3.3. Antivenom administration and clinical observation
In previous clinical trials performed in humans affected by
snakebite envenoming, it was determined that intravenous
administration of this antivenom formulation, at the same dose
used in this study (0.4 mL/kg), induces an incidence of anaphylac-
toid reactions of 15e20% [11,15]. In contrast, our observations
indicate that, during the following 3 h after the administration of
Fig. 1. Electrophoregram of equine-derived antivenom, constituted by whole IgG
molecules. Non-reduced samples were loaded in a 7.5% polyacrylamide gel in the
presence of SDS. Proteins were stained with Coomassie Brilliant Blue R-250. Lane 1
corresponds to puriﬁed antivenom, while lane 2 corresponds to equine plasma. Bands
corresponding to ﬁbrinogen, albumin and immunoglobulins are identiﬁed.
Fig. 2. Gel ﬁltration fast-protein liquid chromatography (FPLC) proﬁle of equine-
derived antivenom, constituted by whole IgG molecules. Antivenom samples were
analyzed in a Superdex 200 10/300 GL column using 20 mM TriseHCl, 150 mM NaCl,
pH 7.5 as eluent. The ﬂow rate was 0.5 mL/min. Peaks labeled as a,b,c and d correspond
to protein aggregates (2.5%), immunoglobulin dimers (6.5%), immunoglobulin mono-
mers (90.5%) and albumin (0.5%), respectively.
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antivenom, none of the animals used in this study showed mani-
festations of early adverse reactions of any type. Moreover, no late
adverse reactions, i.e. rash, were observed during a 40-day period
after antivenom administration.
The difference between studies performed in humans and this
study in animals could be attributed to the fact that a number of
reactions such as nausea, headache and dizziness are readily
recorded in humans, but not in animals. However, the majority of
the clinical manifestations of anaphylactoid reactions, such as fever,
vomiting, diarrhea, urticaria, generalized rash, tachypnea or
tachycardia, which are easily detected in both human and animals,
were not observed in our study, thus supporting the conclusion that
early adverse reactions were absent in horses and cows after
administration of this antivenom.
Another factor that must be considered is the fact that, unlike
studies performed in envenomed humans, our present results were
obtained in a group of non-envenomed individuals. Incidence of
early adverse reactions induced by this antivenom formulation in
envenomed animals has not been determined yet. The impact of
this methodological difference on the incidence of early adverse
reactions to antivenoms is unclear at present. Our results might be
revealing a different tolerability towards equine-derived immu-
noglobulins in horses and cows as compared to humans.
Assuming that the incidence of anaphylactoid reactions to
antivenom administration varies between different species, this
agrees with the hypothesis that natural anti-species antibody
responses of patients against foreign proteins are likely to be
involved in the genesis of anaphylactoid reactions [7,8,32]. Thus,
sensitization of animals and humans with heterologous horse
immunoglobulins, through a variety of mechanisms different
from therapeutic antibody administration, may explain the
presence of heterophilic anti-horse IgG which may react with
horse IgG upon antivenom infusion, provoking anaphylactoid
reactions. From this point of view, it is not surprising that horses
did not suffer anaphylactoid reactions when exposed to homol-
ogous antivenoms.
3.4. Determination of anti-equine antibodies in the plasma of
treated cows
The genesis of anaphylactoid reactions could be related to het-
erophilic antibodies that occur naturally in the plasma of animals or
humans towards the immunoglobulins that constitute the anti-
venom [7,8,32]. We found that cows have a basal antibody titre
against equine IgG, which is very similar in all animals tested
(Fig. 3). Since no early adverse reactions were registered, it is clear
that this basal anti-equine antibody titre is unlikely to play a rele-
vant role in the pathogenesis of anaphylactoid reactions in cows.
However, as shown in Fig. 3, 40 days after the administration of
antivenom, the concentration of antibodies against equine IgG
increased signiﬁcantly (t ¼ 2.790, df ¼ 9, P ¼ 0.021). Thus, equine
antivenom IgG stimulates an antibody response in cows, a ﬁnding
thatmay bear relationship to the potential development of a type III
hypersensitivity reaction, i.e. serum sickness [20]. However, clinical
inspection of animals did not reveal evidence of immune complex
reactions, i.e. no rash development occurred, at the time anti-
equine antibody response developed.
3.5. Determination of sensitization of bovine erythrocytes by
antivenom antibodies
Agglutination and lysis of erythrocytes by heterologous serum
was described for the ﬁrst time in 1875 by Leonard Landois [33].
Fig. 3. Determination of bovine antibodies against horse immunoglobulins. ELISA
plates were coated with 100 mL of antivenom (5 mg protein/dL). Then, 100 mL of bovine
serum samples, diluted 1:1000 in PBS-2% bovine milk (BM), were added. Anti-equine
antibodies were detected with a rabbit anti-bovine IgG conjugated with peroxidase,
diluted 1:8000. Results are presented as the absorbances at 492 nm (mean  SD) of
a 1:1000 serum dilution. Absorbance of the control of PBS-2% BMwas 0.450  0.021. *A
signiﬁcant increment (P < 0.001) in absorbance was observed between samples taken
immediately before and 40 days after antivenom administration.
Table 1
Agglutination of erythrocytes from non-envenomed cows, by equine-derived antivenom.
in vitro sensitization in vivo sensitization
Cow number Direct agglutinationa Before antivenom Before antivenom After antivenom
Antiglobulin testb NRSc Antiglobulin test NRS Antiglobulin test NRS
1  þ     
2  þ     
3  þ     
4  þ     
5  þ     
6  þ     
7  þ     
8  þ     
9  þ     
10  þ     
a Antivenom diluted 1:10 was incubated with a 5% suspension of bovine erythrocytes in PBS. After centrifugation, agglutination was observed macroscopically and graded
from e (no agglutination) to 4þ (strong agglutination).
b Antiglobulin test was carried out using a rabbit anti-equine IgG. For in vitro sensitization, erythrocytes were incubated with antivenom in vitro, and then tested by the
antiglobulin test. For in vivo sensitization, cows received antivenom intravenously (0.4 mL/kg) and then a blood sample was collected and erythrocytes tested for the
antiglobulin test (see Materials and methods for details). A blood sample was also collected immediately before antivenom administration.
c Normal rabbit serum was used as control of the antiglobulin test.
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Afterwards, it was demonstrated that serum haemolytic activity
depends on the species used as complement, antibodies or eryth-
rocytes sources [34]. Inability of complement system to lyse
sensitized erythrocytes may be due either to: 1) non-activation of
the complement system by the heterologous immunoglobulins, or
2) activation of the complement system over erythrocytes resistant
to lysis [34].
Natural heterophilic anti-erythrocyte antibodies can be dragged
along antivenom production from the initial plasma to the ﬁnal
product [22]. Therefore, administration of heterologous anti-
venoms to animals could result in intravascular haemolysis due to
the action of such anti-erythrocyte antibodies. Also, a non-hae-
molytic complement ﬁxation could result in anaphylatoxins release
and consequently in the induction of the early adverse reactions
observed during the antivenom administration.
As expected, the equine antivenom used in this study does not
have antibodies against horse erythrocytes (not shown). However,
it has natural antibodies against bovine erythrocytes. These anti-
bodies are capable of mediating the agglutination of erythrocytes
sensitized in vitro; nevertheless, due to their very low concentra-
tion, sensitization in vivo was undetectable in our experimental
conditions (Table 1). These observations, together with the fact that
no evident early adverse reactions occurred in cows, suggest that
natural anti-bovine erythrocyte antibodies present in equine-
derived antivenom do not provoke adverse reactions in these
bovines. Nevertheless, these ﬁndings cannot be extrapolated to
other species and other animal sources of antivenom [34].
4. Conclusions
Polyvalent antivenom consisting of whole IgG puriﬁed from
equine plasma by caprylic acid precipitation is routinely used in
Central America in the treatment of viperid snakebite envenoming
in humans and animals [35]. Our observations indicate that this
antivenom is very well tolerated by horses and cows, i.e. no early
adverse reactions occurred after bolus intravenous administration.
Although it is necessary to extend these observations to enve-
nomed horses and cows, our results and previous observations
suggest that, in addition to the physicochemical characteristics of
the formulation, other factors must determine the manifestation of
adverse reactions in snakebite envenomed humans treated with
equine-derived antivenoms. The conclusions reached in this study
cannot be extrapolated to antivenoms manufactured using other
animal sources of antivenom, and further investigations are
necessary to assess this hypothesis.
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